Industry Briefs: October 22, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: October 22, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AMRI has extended its API supply agreement with Shire. Read More

Aptuit has announced the offering of antibacterial studies from a single site, the Aptuit Center for Drug Discovery & Development in Verona, Italy.

The National Institute of Allergy and Infectious Diseases has awarded Pfenex a contract to develop an alternative delivery method for its recombinant protective antigen (rPA)-based anthrax vaccine. Read More

Pluristem Therapeutics has achieved a milestone towards the completion of its new GMP manufacturing facility for commercial production of the company’s Placental eXpanded cells. Read More

The United States Pharmacopeial Convention (USP) has selected the Thermo Scientific TruScan RM and microPHAZIR RX instruments to support its recent initiative to provide USP-approved spectral libraries to pharmaceutical manufacturers. Read More

People News

AMRI has appointed Steven R. Hagen as senior vice-president of pharmaceutical development and manufacturing. Read More

Cobra Biologics has appointed John Birch, former chief scientific officer for Lonza Biopharmaceuticals, as a nonexecutive director. Read More

ISPE has announced its 2012–2013 board of directors election results, including Charlotte Enghave Fruergaard as chair and Damian Greene as vice-chair. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here